A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Interpretation of nanoparticle PK results can be markedly influenced by differing PK metrics selected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Comparisons between %ID in tumor and traditional PK metrics for all datasets (i.e., all types of nanoparticles). Correlation plots for all datasets between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) [ρ = 0.183 all data (AD); ρ = 0.151 excluding outliers (EO)] and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.319 AD; ρ = 0.289 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.562 AD; ρ = 0.572 EO).](https://figures.cochat.ai/paper-figures/800c7ec305d0438ea04d8675852da227/a-reanalysis-of-nanoparticle-tumor-delivery-using-classical-pharmacokinetic-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The conclusion was that the %ID in tumor was poorly correlated with the standard PK metrics which describe nanoparticle tumor delivery (AUCtumor/AUCblood ratio).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“The relative tumor delivery of nanoparticles was ~100-fold greater as assessed by the standard AUCtumor/AUCblood ratio than by %ID in tumor.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“A recent reanalysis by Price et al., based on the same dataset, has cast major doubt on the validity of Wilhelm et al. conclusions [244].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 3×
“(19) However, the conclusions of the study by Wilhelm et al.”
BackgroundResultStatistics corner: A guide to appropriate use of correlation coefficient in medical research.
(2012) · Europe PMC (PubMed Central) · Cited by 4,239
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Self-citationA Safe‐by‐Design Strategy towards Safer Nanomaterials in Nanomedicines
Yan, L., Zhao, F., Wang, J., Zu, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805391 · Cited by 183 · cited 1×
“In 2017 alone, there were more than 300 nanomedicine patent filings, with more than half related to drug delivery (3).”
BackgroundConcept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
Zamboni, W. C. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0180 · Cited by 173 · cited 1×
“Examples of various types of NPs include liposomes, polymeric micelles, fullerenes, carbon nanotubes, quantum dots, nanoshells, polymers, dendrimers, and conjugates, including antibody-drug conjugates (9).”
BackgroundSelf-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Metadata
- Authors
- Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Corresponding author
- Zamboni, William C.
- Venue
- Science Advances
- Published
- 2020-07-17
- Volume
- 6
- Issue
- 29
- Pages
- eaay9249-eaay9249
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7439617
- OpenAlex
- W3042603832
- Cited by
- 128
- References
- 21
- Citations by year
- 2026: 20 · 2025: 14 · 2024: 21 · 2023: 24 · 2022: 19 · 2021: 21 · 2020: 9
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina - Chapel Hill (1U54CA19899-01 Pilot Grant)
- Carolina Cancer Nanotechnology Training Program (1T32CA196589, R01CA184088)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- pharmacokinetics, tumor biodistribution, nanotherapeutics, reanalysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. https://app.cochat.ai/papers/10.1126/sciadv.aay9249
- The paper
- Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C. (2020). A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. Science Advances. https://doi.org/10.1126/sciadv.aay9249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.